NewsRx

Search our medical news database

HIV Vaccines

Modified Canarypox Vector Shows Promise

Published in Vaccine Weekly, March 21st, 2001

by Michael Greer, staff medical writer -- A novel HIV vaccine has shown encouraging results in early studies, researchers in Washington state report.

L. Corey and colleagues at the Fred Hutchinson Cancer Research Center in Seattle evaluated the efficacy of a vaccine made up of a recombinant gp120 protein delivered via a canarypox vector containing the HIV proteins Gag, Env, and Pro.

They found that their vaccine elicited both memory T-cell and HIV specific antibody responses in a majority of the volunteers. More than six out of 10 (62%) of the study participants showed CD8+ T-cell responses, study data showed, while over 90% developed HIV...

Want to see the full article?

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now


Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly


NewsRx is Social

Follow us on your favorite social network by clicking on a button below:

Follow NewsRx on Twitter

NewsRx on Facebook

Awards

eHealthcare Leadership 2011 Winner
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

  • Google 2010 PageRank: #2 Among Top Health News and Media Publications
  • Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
  • Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
  • Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx on Facebook